Skip to main content

Itamar Medical Appoints Brad Fluegel to its Board of Directors

Written by Customer Service on . Posted in Public Companies.

CAESAREA, Israel, May 24, 2021 (GLOBE NEWSWIRE) — Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today announced the appointment of Brad Fluegel to its Board of Directors.

Mr. Fluegel’s vast experience includes wide ranging leadership roles and 25+ years in the healthcare sector, primarily in strategy and business development. Most recently, Mr. Fluegel was Senior Vice President, Chief Healthcare Commercial Market Development Officer for Walgreens Co. In this role he was responsible for driving all commercial healthcare activities, including sales and contracting, biopharma relationships, retail clinics, clinical affairs, new service development and market planning. Prior, he served as Walgreens’ Chief Strategy and Business Development officer. Prior to Walgreens, Mr. Fluegel was executive in residence at Health Evolution Partners. Earlier in his career, he was Executive Vice President, Chief Strategy and External Affairs Officer at Wellpoint (now Anthem) and as CEO for Reden & Anders and Tillinghast-Towers Perrin, a clinical, actuarial and management consulting practice serving all sectors of the health care industry.

“We are delighted to welcome Brad to Itamar’s board,” said Dr. Giora Yaron, Chairman of Itamar’s Board of Directors. “His extensive and impressive experience working with large scale international companies in the Direct to Consumer, or DTC space, as well as the healthcare retail segment will serve as an extraordinary resource for Itamar’s future growth plans.”

Mr. Fluegel currently serves on the Board of Directors of Metropolitan Jewish Health System in New York City, Performant Financial Corporation, Premera Blue Cross, Alight Solutions and AdhereHealth.

Mr. Fluegel earned a master’s degree in public policy from Harvard University and a bachelor’s degree in business administration from the University of Washington.

About Itamar Medical Ltd.
Itamar Medical is a medical technology company focused on the development and commercialization of non-invasive medical devices and solutions to aid in the diagnosis of respiratory sleep disorders. Itamar Medical commercializes a digital healthcare platform to facilitate the continuum of care for effective sleep apnea management with a focus on the core sleep, cardiology and direct to consumer markets. Itamar Medical offers a Total Sleep Solution to help physicians provide comprehensive sleep apnea management in a variety of clinical environments to optimize patient care and reduce healthcare system costs. The Company’s key product, WatchPATTM, is commercially available within major markets including the US, Japan, and Europe. Itamar Medical is a public company traded on the Nasdaq and on the Tel Aviv Stock Exchanges, and is based in Caesarea, Israel with U.S. headquarters based in Atlanta, GA. For additional information visit www.itamar-medical.com

Itamar Medical Investor Relations Contact (U.S.)

Leigh Salvo
Gilmartin Group
Phone: +1-510-693-5238
investors@itamar-medical.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.